P2Y purinoceptor 12 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13P2Y purinoceptor 12 shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9H244. Start with myocardial infarction, then reuse UniProt Q9H244 as the stable protein anchor across project notes and exports.
Start with myocardial infarction, then reuse UniProt Q9H244 as the stable protein anchor across project notes and exports.
P2Y purinoceptor 12 shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block. 10 linked drugs remain visible in the same block.
Start review with myocardial infarction because it currently carries approved-linked support. Linked drugs include CANGRELOR, CANGRELOR TETRASODIUM, CLOPIDOGREL BESILATE, CLOPIDOGREL BISULFATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyP2Y purinoceptor 12
Review this target as P2Y purinoceptor 12, mapped to UniProt Q9H244. Sequence length is 342 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats P2Y purinoceptor 12 as ChEMBL target CHEMBL2001, mapped to UniProt Q9H244. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether P2Y purinoceptor 12 is the right protein anchor across sources, using UniProt Q9H244 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why myocardial infarction is currently framed as approved-linked support. It currently carries 10 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | P2Y purinoceptor 12 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q9H244 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | P2Y purinoceptor 12 |
| UniProt Accession | Q9H244 |
| Component Type | Protein |
| Sequence Length | 342 aa |
P2Y purinoceptor 12
Review this target as P2Y purinoceptor 12, mapped to UniProt Q9H244. Sequence length is 342 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
P2Y purinoceptor 12 shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block.
Start review with myocardial infarction because it currently carries approved-linked support. Linked drugs include CANGRELOR, CANGRELOR TETRASODIUM, CLOPIDOGREL BESILATE, CLOPIDOGREL BISULFATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL455536 | 9.8 | Kd | 0.1585 | Preclinical |
| CHEMBL251041 | 9.6 | Ki | 0.2512 | Preclinical |
| CHEMBL5181634 | 9.52 | Ki | 0.3 | Preclinical |
| CHEMBL251024 | 9.5 | IC50 | 0.3162 | Preclinical |
| CHEMBL5176593 | 9.48 | IC50 | 0.33 | Preclinical |
| CHEMBL570295 | 9.42 | Ki | 0.38 | Preclinical |
| CHEMBL567915 | 9.4 | Ki | 0.4 | Preclinical |
| CHEMBL334966 | 9.4 | IC50 | 0.3981 | Approved |
| CHEMBL567561 | 9.34 | Ki | 0.46 | Preclinical |
| CHEMBL437204 | 9.3 | IC50 | 0.5012 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 31 | 806 | 7.5 |
| single protein format | 26 | 75 | 6.9 |
| assay format | 21 | 159 | 6.4 |
| tissue-based format | 8 | 26 | 5.5 |
| cell membrane format | 5 | 10 | 7.3 |
| cell-free format | 4 | 35 | 5.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 28 | 172 | 6.1 |
| cell-based format | 15 | 89 | 6.3 |
| cell-free format | 9 | 222 | 5.8 |
| cell membrane format | 1 | 3 | 7.7 |
| single protein format | 1 | 3 | 7.3 |
| tissue-based format | 1 | 0 | — |